Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

SingletO2 Therapeutics LLC
Profile last edited on: 6/8/23      CAGE: 7FMM6      UEI: H17BGQ86LAR4

Business Identifier: New treatments utilizing power of Singlet Oxygen
Year Founded
2015
First Award
2016
Latest Award
2021
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

28 Morehouse Place
New Providence, NJ 07974
   (908) 499-8126
   N/A
   www.singleto2.com
Location: Single
Congr. District: 07
County: Union

Public Profile

Headed up by a longtime NIH funded professor, the team of scientists assembled by SingletO2 Therapeutics LLC are developing a breakthrough treatment for periodontal disease. The firm's therapy - harnessing the bacteria-killing capability of singlet oxygen - is designed and intended to treat advanced stages of the disease without surgery.

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
1
Conversion Rate
50.00%
Phase I Dollars
$404,506
Phase II Dollars
$1,592,465
Total Awarded
$1,996,971

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2021 1 NSF $255,999
Project Title: Safe Disinfection and Oxygen-Level Enrichment in Recirculating Aquaculture Systems (RAS) Using Singlet Oxygen
2020 2 NIH $1,740,972
Project Title: Superhydrophobic Implantable Surface and 3D Printing Technology for Targeted Dental Photodynamic Therapy

Key People / Management

  Alan Lyons -- CEO and COO

  Alexander Greer -- CTO

  Amy Lyons

  Qianfeng Xu

Company News

There are no news available.